Organigram Global Inc. (OGI) stock

OGINasdaqPharmaceutical PreparationsFiscal year ends September 30

Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 40-F on Dec 16, 2025Score 4/30

$0.83−0.01 (-0.65%)

Close on Nov 13, 2026Market cap $111.41MP/E –Yield –

Organigram Global r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was C$10.95M, up 83.6% from the year before. The highest annual figure on record is C$10.95M in fiscal 2025.

Period	Period end	Value	Change
FY2025	Sep 30, 2025	C$10.95M	+83.6%
FY2022	Aug 31, 2022	C$5.96M	+63.6%
FY2021	Aug 31, 2021	C$3.65M	+187.2%
FY2020	Aug 31, 2020	C$1.27M	+210.3%
FY2019	Aug 31, 2019	C$409.00K	–
FY2018	Aug 31, 2018	C$0	–

Parsed from the XBRL in Organigram Global's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-4 reverse split on Dec 19, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is OGI.

Revenue growth77.8% · median 10.7%

Gross margin34.8% · median 35.9%

Operating margin-5.9% · median 1.3%

Advertisement
300 × 250

See a number that looks wrong?